505 related articles for article (PubMed ID: 27909053)
21. Cholesterol in LDL receptor recycling and degradation.
Yang HX; Zhang M; Long SY; Tuo QH; Tian Y; Chen JX; Zhang CP; Liao DF
Clin Chim Acta; 2020 Jan; 500():81-86. PubMed ID: 31770510
[TBL] [Abstract][Full Text] [Related]
22. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
[TBL] [Abstract][Full Text] [Related]
23. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
24. Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network.
Chae HS; You BH; Kim DY; Lee H; Ko HW; Ko HJ; Choi YH; Choi SS; Chin YW
Sci Rep; 2018 Apr; 8(1):6737. PubMed ID: 29712938
[TBL] [Abstract][Full Text] [Related]
25. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
[TBL] [Abstract][Full Text] [Related]
26. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
27. Dynamin-related protein 1 inhibition reduces hepatic PCSK9 secretion.
Rogers MA; Hutcheson JD; Okui T; Goettsch C; Singh SA; Halu A; Schlotter F; Higashi H; Wang L; Whelan MC; Mlynarchik AK; Daugherty A; Nomura M; Aikawa M; Aikawa E
Cardiovasc Res; 2021 Sep; 117(11):2340-2353. PubMed ID: 33523181
[TBL] [Abstract][Full Text] [Related]
28. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
[TBL] [Abstract][Full Text] [Related]
29. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
30. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
31. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
32. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
Li X; Hu X; Pan T; Dong L; Ding L; Wang Z; Song R; Wang X; Wang N; Zhang Y; Wang J; Yang B
Biomed Pharmacother; 2021 Jan; 133():110802. PubMed ID: 33202286
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Maxwell KN; Fisher EA; Breslow JL
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
[TBL] [Abstract][Full Text] [Related]
34. Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells.
Ali A; Unnikannan H; Shafarin J; Bajbouj K; Taneera J; Muhammad JS; Hasan H; Salehi A; Awadallah S; Hamad M
Endocrine; 2022 Jun; 76(3):543-557. PubMed ID: 35237909
[TBL] [Abstract][Full Text] [Related]
35. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
[TBL] [Abstract][Full Text] [Related]
36. Hydrogen sulfide inhibits PCSK9 expression through the PI3K/Akt‑SREBP‑2 signaling pathway to influence lipid metabolism in HepG2 cells.
Xiao J; Bai XQ; Liao L; Zhou M; Peng J; Xiang Q; Ren Z; Wen HY; Jiang ZS; Tang ZH; Wang MM; Liu LS
Int J Mol Med; 2019 May; 43(5):2055-2063. PubMed ID: 30864739
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia.
Zou Y; Li S; Xu B; Guo H; Zhang S; Cai Y
Inflammation; 2020 Feb; 43(1):251-263. PubMed ID: 31776890
[TBL] [Abstract][Full Text] [Related]
38. Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE
Gu L; Gong Y; Zhao C; Wang Y; Tian Q; Lei G; Liang Y; Zhao W; Tan S
Molecules; 2019 Nov; 24(22):. PubMed ID: 31731717
[TBL] [Abstract][Full Text] [Related]
39. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.
Syed GH; Tang H; Khan M; Hassanein T; Liu J; Siddiqui A
J Virol; 2014 Mar; 88(5):2519-29. PubMed ID: 24352472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
